Send this to a friend

Biostage combines stock 20:1 to satisfy $4M private investor

In order to complete a $4-million deal with a private investor and save the company from insolvency, Holliston biotech Biostage has performed a 20:1 reverse stock split. 
The reverse stock split reduced the number of Biostage shares from 39.8 million to 2 million. As a result of having fewer shares on the market, the company's stock price went up from 6.6 cents per share to 91 cents when the markets closed on Tuesday. 
Back to article

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media